A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10914-10919

  Duffy, Margaret R ^a   Bradshaw, Angela C ^a   Parker, Alan L ^a   McVey, John H ^b   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMINO ACID; BLOOD CLOTTING FACTOR 10; PROTEOHEPARAN SULFATE;

ADENOVIRUS 5; ARTICLE; BINDING SITE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTACHMENT;

ADENOVIRIDAE; AMINO ACID SUBSTITUTION; AMINO ACIDS, BASIC; FACTOR X; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

HUMAN ADENOVIRUS TYPE 5;

EID: 80055019114     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05382-11     Document Type: Article

References (15)

1. Alba, R., et al. 2009. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114:965-971.
2. Bradshaw, A. C., et al. 2010. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog. 6:e1001142.
3. Camire, R. M., P. J. Larson, D. W. Stafford, and K. A. High. 2000. Enhanced γ-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry 39:14322-14329.
4. Kalyuzhniy, O., et al. 2008. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U. S. A. 105:5483-5488.
5. Kim, D. J., and H. L. James. 1994. Expression of human factor X with normal biological activity in human embryonic kidney cells. Biotechnol. Lett. 16:549-554.
6. Kim, M., et al. 2002. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur. J. Cancer 38:1917-1926.
7. Monteiro, R. Q., A. R. Rezaie, J. M. Ribeiro, and I. M. Francischetti. 2005. Ixolaris: a factor Xa heparin-binding exosite inhibitor. Biochem. J. 387:871-877.
8. Murakami, M. T., et al. 2007. Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum. J. Mol. Biol. 366:602-610.
9. O'Brien, D. P., et al. 1994. Surface plasmon resonance studies of the interaction between factor VI1 and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 33:14162-14169.
10. Padmanabhan, K., et al. 1993. Structure of human des(1-45) factor Xa at 2.2 A resolution. J. Mol. Biol. 232:947-966.
11. Parker, A. L., et al. 2006. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes in vitro and in vivo. Blood 108:2554-2561.
12. Rezaie, A. R. 2000. Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J. Biol. Chem. 275:3320-3327.
13. Shayakhmetov, D. M., A. Gaggar, S. Ni, Z. Y. Li, and A. Lieber. 2005. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79:7478-7491.
14. Vigant, F., et al. 2008. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol. Ther. 16:1474-1480.
15. Waddington, S. N., et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397-409.